Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy

Belle L. Lee, Ana M. Padula, Robert C. Kimbrough, Stephen R. Jones, Richard E. Chaisson, John Mills, Merle A. Sande

Research output: Contribution to journalLetterpeer-review

Abstract

To the Editor: Ciprofloxacin, a fluoroquinolone, is widely used for a broad range of infections.1 Although it has had some success in treating respiratory tract infections, delayed clinical responses and the failure to eradicate pathogens from sputum have been reported in some patients with Streptococcus pneumoniae2 In addition, its in vitro activity against gram-positive cocci is marginal.1 3 Minimal inhibitory concentrations for S. pneumoniae and group A streptococcus range from 1 to 4 μg per milliliter, whereas the maximal serum level achieved after a 500-mg oral dose is approximately 2.5 μg per milliliter.4 We report here the cases of six patients. . .

Original languageEnglish (US)
Pages (from-to)520-521
Number of pages2
JournalNew England Journal of Medicine
Volume325
Issue number7
DOIs
StatePublished - Aug 15 1991

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy'. Together they form a unique fingerprint.

Cite this